BioDesign Innovation

The Bristol biodesign companies listed below have:
 
  • been founded directly on IP generated through BrisSynBio; or
  • benefitted from substantial BrisSynBio investment and dedicated innovation support; or
  • strong links to BrisSynBio and the Bristol BioDesign Institute.

The companies resulting from BrisSynBio have all incorporated since 2017, collectively raised more than £10m in private and innovation investment, and created more than 30 jobs. This demonstrates:

  • the significant success and impact of translating fundamental synthetic biology emanating from BrisSynBio into real-world applications;
  • the appetite of Bristol academics to have a wider impact beyond their academic fields; and
  • the vibrant environment for biotech in and around Bristol.

Companies founded directly on IP generated through BrisSynBio

  • CDotBio is developing novel carbon-based technology for rapid crop adaptations to address the challenges of climate change and food security. It is founded on the discovery that carbon nanoparticles (Carbon Dots) can enter plant cells and has led to the use of these particles to deliver genetic material, simplifying gene editing (GE) and non-GM approaches to creating novel plant traits.
  • Halo Therapeutics aim to solve the urgent need for no home therapeutic treatment for COVID-19 by providing safe, pan coronavirus antivirals which can be applied by COVID-19 patients by themselves, at home.
  • Rosa Biotech aim to provide patients and clinicians with the benefits of early diagnosis of a broad spectrum of diseases by combining the power of protein design and machine learning. Its innovative sensing platform, Pandra, can detect life-threatening diseases with high accuracy in patient samples. 
  • Zentraxa use bioengineering to produce peptides, specifically 'BioBetters', with predictable properties that are tailored to purpose. The spin-out has secured £500k investment to commercialise their proprietary technological platform, Zentide, to produce biological adhesives for the heathcare sector.

Companies that have benefitted from substantial BrisSynBio investment and dedicated innovation support

  • Cytoseek aim to use Artificial Membrane Binding Protein (AMBP) technology to deliver the potential of the next generation of cell therapies, with a focus on treating solid tumours. CytoSeek are developing AMBPs that can provide homing, immunomodulation, and/or hypoxia resistance functionality.
  • Glaia is using revolutionary 'sugar-dots' technology, developed at the University of Bristol, to allow plants to harvest light more efficiently and facilitate the processes involved in biomass production, resulting in increased crop yields. With this technology, Glaia aims to effectively help ensure food security in the future as well as reduce the carbon footprint of agricultural food production.
  • Imophoron is a pre-clinical stage company whose researchers have engineered a novel synthetic protein scaffold named ADDomer™, for creating highly immunogenic vaccine candidates. Proof of concept data for two highly infectious diseases has demonstrated potential to prevent disease and transmission. Unlike most vaccines, their Chikungunya vaccine candidate can be produced and stored without refrigeration. 

Companies with strong links to BrisSynBio and the Bristol BioDesign Institute

  • Carbometrics aim to help people with diabetes live more normal and longer lives. They are using their proprietary Biomimetic Glucose Binding Molecule (GBM) to develop a new glucose sensor chemistry that will enable market-leading Continuous Glucose Monitors (CGM).
  • Folium Science creates alternatives to the need to use antibiotics, by providing precise bacterial control for agricultural production. It has developed a unique and patented technology called Guided Biotics that selectively removes unwanted bacteria. This will help to reduce the need to use antibiotics in farmed animals, support the health of plants, and lead to improved food productivity. 
  • Purespring are developing a proprietary platform and novel treatments focused on targeting the podocyte, a cell type vital to kidney function and health. Purespring's therapies will target rare monogenic diseases, as well as much more prevalent common forms of kidney disease. It is the first gene therapy platform to specifically target kidney diseases. 
  • Vitamica is developing rapid antimicrobial susceptibility testing (AST) of patient samples to inform doctors which antibiotics will be effective and to which the bacteria show resistance. The test results should be available within one hour, rather than the standard 36-48 hours. Preventing the spread of antibiotic resistance is a global challenge of the 21st Century. 
Edit this page